Novel Treatment Review (NTR) Working Group
The haemophilia treatment landscape is fast evolving, with many new and innovative therapies in the final stages of development or being marketed in Europe. To help our members navigate these changes, the EHC has developed a publication, the Novel Treatment Review (NTR) issued twice a year with the latest therapeutic developments.
The work of the NTR Working Group is supported by Roberta Sadauskaite, EHC Public Policy Lead.
Read the NTRs on the EHC Academy
EHC NTR Working Group is composed of:

Dr Paul Batty
United Kingdom
University College London

Prof Jan Blatny
Czech Republic
Consultant Haematologist and Lead Clinician at the Department of Paediatric Haematology, Centre for Thrombosis and Haemostasis at the Children’s University Hospital Brno

Prof Ana Boban
Croatia
Head of Haemophilia Centre at the University Hospital Centre Zagreb, Professor of Internal Medicine at the School of Medicine of the University of Zagreb

Panagiotis Christoforou
Greece
Steering Committee Member

Miguel Crato
Portugal
President

Mariëtte Driessens
The Netherlands
Dutch EHC NMO

Radoslaw Kaczmarek
Indiana University School of Medicine, Indianapolis, USA
Post-doctoral Research Associate

Ilmar Kruis
The Netherlands
Dutch EHC NMO

Dr Maria Elisa Mancuso
Italy
MAG Chair, Centre for Thrombosis and Haemorrhagic Diseases, IRCCS Humanitas Research Hospital and Humanitas University Rozzano

Brian O’Mahony
Chief Executive of the Irish Haemophilia Society, Dublin, Ireland
Former President of the EHC

Prof Johannes Oldenburg
Institute of Transfusion Medicine and Immuno-haematology, Bonn University, Germany
Head of the Department of Immuno-haematology and the Department of Molecular Haemostasis

David Page
Canada
Canadian Haemophilia Society

Uwe Schlenkrich
Germany